Arterial stiffness is a key determinant of cardiovascular risk in hypertensive patients. β-
Blockers appear to be less effective than other drugs in improving outcome in hypertensive …

Arterial stiffness plays a key role in the pathophysiology of the cardiovascular system. Some
indices of arterial stiffness (pulse wave velocity, augmentation index, characteristics of …

Background Vascular endothelial dysfunction may predict future atherosclerosis. Hence, an
antihypertensive agent that reverses endothelial dysfunction and lowers blood pressure …

Nebivolol (Bystolic®) is a cardioselective beta 1 (β1)‐adrenergic receptor blocker with
endothelium‐dependent vasodilating properties. The endothelium‐dependent relaxation …

Background There is conflicting information with regard to the effect of β-blockers on arterial
stiffness and wave reflection. We compared a vasodilating β-blocker, nebivolol, with …

Pulse wave velocity (PWV) reflects arterial stiffness and is an independent predictor of
cardiovascular mortality and morbidity. However, because it is closely related to blood …

New evidence from recently completed clinical studies performed with nebivolol, a highly
selective beta‐1 β‐blocker, endowed with additional vasodilating activity mediated by nitric …

Background: Nebivolol is a selective β1-adrenergic receptor antagonist that causes a direct
vasodilator effect attributed to the action on vascular nitric oxide (NO). This study aimed to …

Nebivolol is a vasodilating β-blocker, which can be distinguished from other β-blockers by its
haemodynamic profile. It combines β-adrenergic blocking activity with a vasodilating effect …

Nebivolol is a new and selective β 1‐adrenergic receptor antagonist whose haemodynamic
profile is different from that of classical β‐blockers. The blood pressure lowering effects of …